HIMS post-earnings revenue turns to net loss, on-chain price briefly spikes down 10%

November 10 - Hims & Hers today released its third-quarter financial report, with quarterly revenue up 49% year-over-year to $890 million, but gross margin fell from 74% in the same period last year to 57%, and net profit swung from a profit of $15.8 million to a loss of $33 million.

Profit guidance was also cut. The company lowered its full-year 2026 adjusted EBITDA forecast from the previous $275 million to $325 million down to $257 million to $277 million, a decline of about 11% at the midpoint. Full-year revenue guidance was narrowed to $3.13 billion to $3.15 billion.

According to TradingBeats monitoring, after the earnings release, the HIMS perpetual contract on Hyperliquid saw a notable wick. Around 05:08, the traded price briefly dropped to $20.57, down about 10.4% from $22.95 before the announcement; it then rebounded quickly and reclaimed $23 about half an hour later.

As of press time, the contract is quoted at about $22.14, down about 14.8% in the past 24 hours and still about 3.6% lower than before the earnings release; trading volume during the period was about $11.43 million, with notional open interest valued at about $3.22 million.

By comparison, the Moderna contract rose about 5.9% over the same period to $271.66. Moderna reported third-quarter net profit of about $162 million on November 6 and raised its full-year revenue growth forecast from no more than 10% to 15%–25%.